User: Guest  Login
Title:

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.

Document type:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Article
Author(s):
Kutsch, Nadine; Busch, Raymonde; Bahlo, Jasmin; Mayer, Jiri; Hensel, Manfred; Hopfinger, Georg; Hess, Georg; von Grünhagen, Ulrich; Wendtner, Clemens-Martin; Maria Fink, Anna; Fischer, Kirsten; Hallek, Michael; Eichhorst, Barbara
Abstract:
The chemoimmunotherapy FCR (fludarabine and cyclophosphamide with rituximab) is the standard first-line treatment for physically fit chronic lymphocytic leukemia (CLL) patients. To assess the risks and benefits, we investigated health-related quality of life (HRQOL). 817 untreated CLL patients received either FC or FCR within the GCLLSG CLL8 trial. The European Organization for Research and Treatment of Cancer Quality of life Questionnaire C30 was sent to all patients at baseline, after 3, 6, an...     »
Journal title abbreviation:
Leuk Lymphoma
Year:
2017
Journal volume:
58
Journal issue:
2
Pages contribution:
399-407
Language:
eng
Fulltext / DOI:
doi:10.1080/10428194.2016.1190966
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/27357445
Print-ISSN:
1042-8194
TUM Institution:
Institut für Medizinische Statistik und Epidemiologie
 BibTeX